Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PEPG 
PepGen Ltd (PEPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PEPG (3-star) is a STRONG-BUY. BUY since 22 days. Simulated Profits (152.06%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 236.24% | Avg. Invested days 24 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 329.94M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 5 | Beta 1.97 | 52 Weeks Range 0.88 - 8.95 | Updated Date 10/17/2025 |
52 Weeks Range 0.88 - 8.95 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.44% | Return on Equity (TTM) -85.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 292396097 | Price to Sales(TTM) - |
Enterprise Value 292396097 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.11 | Shares Outstanding 68737224 | Shares Floating 19166191 |
Shares Outstanding 68737224 | Shares Floating 19166191 | ||
Percent Insiders 0.13 | Percent Institutions 59.54 |
Upturn AI SWOT
PepGen Ltd
Company Overview
History and Background
PepGen Ltd. is a biotechnology company focused on developing oligonucleotide therapies for neuromuscular and other diseases. Founded in 2018, it has rapidly advanced its Enhanced Delivery Oligonucleotides (EDO) platform.
Core Business Areas
- Oligonucleotide Therapeutics: Develops therapies targeting the root cause of genetic diseases using its EDO platform.
- Neuromuscular Diseases: Focuses on treatments for Duchenne muscular dystrophy (DMD) and other neuromuscular disorders.
Leadership and Structure
James McArthur (CEO), Adam Elikan (CFO). The company has a research and development-focused organizational structure.
Top Products and Market Share
Key Offerings
- PGEN-EDO51 (DMD): A therapeutic candidate for DMD amenable to exon 51 skipping. Currently in clinical trials. Competitors include Sarepta Therapeutics (SRPT) with Exondys 51.
- PGEN-EDO50 (DMD): A therapeutic candidate for DMD amenable to exon 50 skipping. Currently in clinical trials. Competitors include Sarepta Therapeutics (SRPT) developing a similar product.
Market Dynamics
Industry Overview
The oligonucleotide therapeutics market is growing rapidly, driven by advancements in drug delivery and the increasing prevalence of genetic diseases.
Positioning
PepGen is positioned as an innovator in oligonucleotide delivery, with its EDO platform potentially offering improved efficacy and safety compared to existing therapies.
Total Addressable Market (TAM)
The DMD market alone is estimated at several billion USD. PepGen aims to capture a significant share of this market with its EDO platform.
Upturn SWOT Analysis
Strengths
- Novel EDO platform
- Strong intellectual property
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Early-stage clinical development
- Reliance on a single technology platform
- Limited commercial experience
- High cash burn rate
Opportunities
- Expanding the EDO platform to other diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Orphan drug designation and accelerated approval pathways
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- SRPT
- BMY
- VRTX
Competitive Landscape
PepGen's EDO platform offers a potential advantage over existing exon-skipping therapies, but it faces competition from established players like Sarepta with approved products and Bristol Myers Squibb (BMY) & Vertex (VRTX) with competing technologies and extensive resources.
Growth Trajectory and Initiatives
Historical Growth: Growth is reflected in R&D advancements and clinical trial progress rather than revenue.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Advancing clinical trials for PGEN-EDO51 and PGEN-EDO50, expanding its pipeline with new EDO candidates.
Summary
PepGen is a promising biotech company with a novel delivery platform focused on treating neuromuscular diseases. It is still in early-stage clinical development and faces significant risks, but its technology has the potential to disrupt the market. Success depends on clinical trial results and regulatory approval. The company needs to carefully manage its cash burn and navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (limited access)
- Industry News
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Future performance is subject to uncertainty.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PepGen Ltd
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-05-06 | President, CEO, Treasurer, Secretary & Director Dr. James G. McArthur Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://pepgen.com |
Full time employees 62 | Website https://pepgen.com | ||
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.